METTL3 drives NAFLD-related hepatocellular carcinoma and is a therapeutic target for boosting immunotherapy.
Pan Y, Chen H, Zhang X, Liu W, Ding Y, Huang D, Zhai J, Wei W, Wen J, Chen D, Zhou Y, Liang C, Wong N, Man K, Cheung AH, Wong CC, Yu J.
Pan Y, et al. Among authors: ding y.
Cell Rep Med. 2023 Aug 15;4(8):101144. doi: 10.1016/j.xcrm.2023.101144.
Cell Rep Med. 2023.
PMID: 37586322
Free PMC article.